Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial

Abstract

A multicentre, randomized, blinded study compared the efficacy of pradofloxacin with that of a combination of amoxycillin/clavulanic acid in the treatment of deep pyoderma in dogs. Dogs with clinical lesions of deep pyoderma and a positive bacterial culture were included in the study. At each visit, they were evaluated with lesion, pruritus and general condition scores. Dogs were treated either with pradofloxacin at 3 mg kg-1 once daily or with amoxycillin at 10 mg kg-1 and clavulanic acid at 2.5 mg kg-1 twice daily and evaluated weekly for 3 weeks and every 2 weeks thereafter until 2 weeks past clinical remission. Maximal treatment duration was 9 weeks, and maximal evaluation period was 11 weeks. Of the 56 dogs treated with pradofloxacin (group 1), 48 dogs (86%) achieved clinical remission, four dogs improved, four dogs did not respond and a recurrence of clinical signs was not seen in any patient after 11 weeks. Of the 51 dogs treated with amoxycillin/clavulanic acid (group 2), 37 dogs achieved clinical remission (73%), three dogs showed improvement, five dogs showed no response and in six dogs, clinical signs recurred within 2 weeks of cessation of therapy. These results indicate that pradofloxacin is an efficacious therapy comparable to amoxycillin/clavulanic acid for deep bacterial pyoderma in dogs.

Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin

“…Although it is not globally available at this time, a dualtargeting (both topoisomerase IV and DNA gyrase), thirdgeneration fluoroquinolone, pradofloxacin, has shown superior activity in terms of both lower MPC values than other veterinary fluoroquinolones (Wetzstein, 2005) and clinical efficacy against various infections, including UTIs in cats (Litster et al, 2007) and canine pyoderma (Mueller & Stephan, 2007). It has already been suggested that the introduction into the veterinary market of such agents that combine high therapeutic efficacy with a high potential for restricting the selection for fluoroquinolone resistance would promote rational antibacterial-drug therapy in companion animals (Wetzstein, 2005;Litster et al, 2007).…”

“…Escherichia coli is the predominant cause of urinary tract infections (UTIs) in both dogs and cats, and is also isolated frequently from contaminated wounds, surgical infections of the skin and adjacent soft tissues, and deep canine pyodermas (Booth, 2001;Mueller & Stephan, 2007). Although fluoroquinolones belong to one of the most useful classes of antimicrobial agents used to combat various infections, including those caused by E. coli, resistance in canine E. coli isolates to a wide range of fluoroquinolones is increasingly reported (Cohn et al, 2003;Ball et al, 2008).…”

Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography

“…Pradofloxacin is a new compound developed for the management of bacterial infections in dogs and cats, which has been shown to have the highest therapeutic efficacy combined with high potential for restricting the emergence of resistance in comparison with other six veterinary FQs in vitro [4], and a recent multicentre study in vivo showed that pradofloxacin has an efficacious therapy comparable to amoxycillin/clavulanic acid for deep bacterial pyoderma in dogs [5].…”

Comparative activity of pradofloxacin and marbofloxacin against coagulase‐positive staphylococci in a pharmacokinetic–pharmacodynamic model based on canine pharmacokinetics

“…Deep pyoderma, which is often associated with cellulitis, can be difficult to treat because bacteria in lesions are often in the centre of inflammatory foci (Mueller & Stephan, 2007). Pyoderma is mainly caused by Gram‐positive bacteria (most notably coagulase‐positive and coagulase‐negative staphylococci) but also by Gram‐negative bacteria such as Pseudomonas aeruginosa and Escherichia coli (Mueller & Stephan, 2007). The most important pathogen associated with canine pyoderma is Staphylococcus pseudintermedius, a resident of the normal skin (Fitzgerald, 2009).…”